Product Description
aTyr 1940 is a recombinant 506 amino acid version of human histidyl-tRNA synthetase (cytoplasmic isoform 1) (HARS; P12081) [1]. HARS belongs to a novel group of naturally occurring proteins termed 'physiocrines' which are extracellular signaling regions of tRNA synthetases reported to modulate immune system pathways. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=8738)
Mechanisms of Action: RNA Synthetase Analogue
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: aTyr Pharma
Company Location: SAN DIEGO CA 92121
Company CEO: Sanjay S. Shukla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RNN/246/20/KE | N/A |
Not yet recruiting |
Carpal Tunnel Syndrome|Osteoarthritis |
2029-06-15 |
|
| FSHD | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle |
2017-04-18 |
|
| 2016-000624-25 | P2 |
Terminated |
Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Facioscapulohumeral |
2017-04-18 |
|
| 2014-001753-17 | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral |
2017-01-04 |